TITLE  PHASE  CONTACT  LOCATION

A Phase I/II Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)

 I/II

 Deborah Meyer, RN, BGS

 dmeyerk@unmc.edu

(402) 559-6941

or Maribeth Hohenstein

 Nebraska Medical Center, Omaha, NE

Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)

 II

 Deborah Meyer, RN, BGS

 dmeyerk@unmc.edu

(402) 559-6941

or Susan Allen

 Nebraska Medical Center, Omaha, NE

A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma

 II

 Deborah Meyer, RN, BGS

 dmeyerk@unmc.edu

(402) 559-6941

or  Susan Allen

 Nebraska Medical Center, Omaha, NE

STAR-A Phase 2 Single –Arm, Open-Label Study of Single Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in adults Age 60 and Above (USOR 11282)

 II

 Faye Park fpark@nebraskacancer.com, 402-691-6972

Nebraska Cancer Specialists, Omaha

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software